The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Symptom burden, quality of life (QoL), social and behavioral characteristics in young patients (<40 years old) with cancer: A prospective cohort of 7323 patients across 110 sites in France and Belgium.
 
Kaïssa Ouali
Consulting or Advisory Role - Amgen; Anaveon; Sotio
Travel, Accommodations, Expenses - Amgen; Eisai; Sotio
 
Christophe Massard
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Blueprint Medicines; BMS; Celgene; Debiopharm Group; Faron Pharmaceuticals; Faron Pharmaceuticals; Faron Pharmaceuticals; Faron Pharmaceuticals; Faron Pharmaceuticals; Genentech/Roche; INNATE PHARMA; IPSEN; Janssen; Lilly; MSD; Novartis; ORION; Pfizer; PharmaMar; Sanofi; Taiho Pharmaceutical
 
Antoine Hollebecque
Honoraria - Amgen; BMS; Eisai; Incyte; MSD Oncology; Relay Therapeutics; SERVIER
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca/MedImmune (Inst); Debiopharm Group (Inst); Gritstone Bio; Incyte (Inst); Lilly (Inst); QED therapeutics; Relay Therapeutics; Sanofi; Spectrum Pharmaceuticals (Inst); Taiho Oncology; Taiho Pharmaceutical
Research Funding - AstraZeneca/MedImmune (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca/MedImmune; Incyte; Lilly; Pierre Fabre; Roche; SERVIER
Other Relationship - Abbvie; Agios; Amgen; argenx; Arno Therapeutics; Astex Pharmaceuticals; AstraZeneca; AVEO; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chugai Pharma; Clovis Oncology; Daiichi Sankyo; Debiopharm Group; Eisai; Exelixis; FORMA Therapeutics; GamaMabs Pharma; Genentech; GlaxoSmithKline; H3 Biomedicine; Innate Pharma; Janssen-Cilag; Kyowa Hakko Kirin; Lilly; Loxo; Lytix Biopharma; MedImmune; Menarini; Merck Sharp & Dohme; Merrimack; Merus; Millenium Pharamceuticals; Nanobiotix; Nektar; Novartis; Octimet; Oncoethix; Onyx; Orion; Oryzon Genomics; Pfizer; Pierre Fabre; Roche; Roche/Genentech; Sanofi/Aventis; SERVIER; Taiho Pharmaceutical; Tesaro; Xencor
 
Yohann Loriot
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Gilead Sciences; Janssen; Loxo/Lilly; Merck KGaA; MSD Oncology; MSD Oncology (Inst); Pfizer (Inst); Pfizer/EMD Serono; Roche; Roche (Inst); Seagen
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BMS (Inst); Exelixis (Inst); Gilead Sciences (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck KGaA (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Tyra Biosciences (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Janssen Oncology; MSD Oncology; Roche; Seagen
 
Aurelien Marabelle
Stock and Other Ownership Interests - Adagene; Centessa Pharmaceuticals; Deka Biosciences; HiFiBiO Therapeutics; HotSpot Therapeutics; Lytix Biopharma; Marengo Therapeutics; Shattuck Labs
Honoraria - ESMO; European Journal of Cancer; Society for Immunotherapy of Cancer
Consulting or Advisory Role - Adagene; Andera; Asgard Therapeutics; Centessa Pharmaceuticals; Daiichi Sankyo Europe GmbH; Deka Biosciences; Grey Wolf Therapeutics; Guidepoint Global; HiFiBiO Therapeutics; Hotspot Therapeutics; ImCheck therapeutics; Innate Pharma; Johnson & Johnson/Janssen; Lytix Biopharma; Medicxi; MSD; Pathios Therapeutics; Pegaone; Pierre Fabre
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Transgene (Inst)
Patents, Royalties, Other Intellectual Property - monoclonal antibodies against CD81 (Stanford University)
Travel, Accommodations, Expenses - HiFiBiO Therapeutics; Marengo Therapeutics; Pathios Therapeutics
Other Relationship - Elsevier
 
Capucine Baldini
Consulting or Advisory Role - Bicycle Therapeutics; Janssen Oncology; Janssen Oncology; Rising Tide Foundation
Research Funding - Foundation BMS (Inst); Foundation BMS (Inst)
Expert Testimony - Abbvie; AstraZeneca; Bristol-Myers Squibb; MSD Oncology; MSD Oncology
Travel, Accommodations, Expenses - Amgen; Janssen Oncology; MSD Oncology; Roche/Genentech
 
Ivan Panico
Employment - Resilience Care
 
Younes Youssfi
Employment - Resilience Care
 
Arlindo Ferreira
Employment - Resilience Care
Honoraria - Gilead Sciences; Merck Sharp & Dohme; Novartis; Roche; Seagen
Travel, Accommodations, Expenses - Daiichi Sankyo Europe GmbH; Lilly
 
Alexandre Yazigi
Employment - Resilience Care
 
Charles Ferté
Employment - Resilience Care
 
Fabrice Barlesi
Consulting or Advisory Role - Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai Europe (Inst); Lilly (Inst); Merck Serono (Inst); Mirati Therapeutics (Inst); MSD Oncology (Inst); Novartis (Inst); Roche/Genentech (Inst); Sanofi (Inst); Takeda (Inst)
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Innate Pharma (Inst); Innate Pharma (Inst); Ipsen (Inst); Lilly (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst); Sanofi/Aventis (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
 
Fabrice Andre
Consulting or Advisory Role - AstraZeneca (Inst); Boston Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); Guardant Health (Inst); Lilly; Lilly (Inst); N-Power Medicine (Inst); Novartis (Inst); Owkin (Inst); Pfizer (Inst); ROCHE (Inst); SERVIER (Inst)
Research Funding - AstraZeneca (Inst); Daiichi (Inst); Guardant Health (Inst); Lilly (Inst); Novartis (Inst); Owkin (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; Novartis; Roche
 
Maria Alice Franzoi
Speakers' Bureau - Novartis (Inst)
Research Funding - Gilead Sciences (Inst); Resilience Care (Inst); Resilience Care (Inst)